Fenofibrate is a fibric acid derivative like clofibrate and gemfibrozil. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.
Fenofibrate was granted FDA approval on 31 December 1993.
Fenofibrate is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides, and Apo B, and to increase HDL-C adults with primary hypercholesterolemia or mixed dyslipidemia. Fenofibrate is also indicated to treat adults with severe hypertriglyceridemia.
Lewai S Abdulaziz, Baghdad, Iraq
Al Kindy College of Medicine, University of Baghdad, Baghdad, Iraq
Dr. Yassin Abdel Ghaffar Charity Center For Liver Diseases & Researches, Cairo, Nasr City, Egypt
National liver istitute, Shibīn Al Kawm, Egypt
苏州大学, Suzhou, Jiangsu, China
University of California, Irvine, Irvine, California, United States
Investigational Site Number :7240003, Pamplona, Navarra, Spain
Investigational Site Number :6160002, Gdansk, Pomorskie, Poland
Investigational Site Number :4840007, Oaxaca, Mexico
Investigational Site Number 2080001, Viborg, Denmark
Investigational Site Number 7240001, A Coruna, Spain
Investigational Site Number 7050001, Ljubljana, Slovenia
South Florida Research Solutions LLC., Pembroke Pines, Florida, United States
Boyett Health Services Inc, Hamilton, Alabama, United States
Longwood Research - Saadat Ansari, MD, LLC, Huntsville, Alabama, United States
Maryland Cardiovascular Specialist, Baltimore, Maryland, United States
Protenium Clinical Research, LLC - Dallas, Dallas, Texas, United States
Centex Studies, Inc., Houston, Texas, United States
Investigational Site Number 392008, Gifu-shi, Japan
Investigational Site Number 392022, Chiyoda-ku, Japan
Investigational Site Number 392039, Hiroshima-shi, Japan
Beijing 302 hospital, Beijing, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.